Loading
Life sciences · Journal article
Advanced Healthcare Materials · September 20, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Radiotherapy (RT) remains a cornerstone in cancer treatment; however, its therapeutic efficacy is often limited by tumor fibrosis and radioresistance, primarily driven by transforming growth factor‐β (TGF‐β) upregulation. To address these challenges, we developed a tris(bipyridyl)ruthenium(II)‐based metal‐organic layer (RuMOL) for siRNA delivery, designed to simultaneously elicit efficient radiosensitization and silence TGF‐β expression, thereby improving tumor response to RT. RuMOL/siRNA demonstrates robust antitumor effects both in vitro and in vivo by reversing fibrosis and potentiating RT‐induced DNA damage. Detailed mechanistic studies reveal that TGF‐β downregulation effectively suppresses fibrosis, enhances tumor perfusion and oxygenation, and mitigates hypoxia‐driven radioresistance, ultimately improving the therapeutic effect of x‐ray irradiation. This innovative platform holds promise as a dual‐functional agent for siRNA‐based gene silencing and RT enhancement in cancer therapy.